Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Cancer 5, 459–467 (1 June 2005) | doi:10.1038/nrc1630
Immunotherapy for pancreatic cancer |[mdash]| science driving clinical progress
&
Abstract
The identification of key signalling pathways involved in immune-system regulation, along with the development of early pancreatic tumours in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
